National Pharmaceutical Pricing Authority (NPPA) should be complimented for directing drug-manufacturing companies to reduce prices of 56 essential medicines. But at the same time, it should ensure some maximum trade-margin on rest other medicines apart from also fixing an upper-limit of profitability on their production-cost.
It is noteworthy that generic medicines with same salt are much-much cheaper than those being sold under popular brand names. In case branded medicines are safer and extra effective than generic medicines, better is to altogether abolish concept of generic medicines.
Even certain generic medicines otherwise supposed to be cheaper have printed ‘Maximum Retail Price’ (MRP) allowing even upto 400-percent trade margins above their respective ex-factory prices. NPAA should also look into pricing medicines in India where same salt is marketed by different companies in varying prices. Antibiotic ‘Ofloxacin’ has Maximum Retail Price (MRP) for 10 tablets of rupees 314.92, 88.00 and 55.00 for same medicine marketed by three different drug-manufacturers.
There are numerous such medicines where drug-manufacturers are cashing their name by earning huge profits. Fancy-packaging is yet other way of charging heavily for medicines. Drug-companies bribe medical-practitioners through costly super-luxury, foreign-trips and many other gifts of every range according to reach of medical-practitioners for recommending their branded medicines. Since retailers are competing by giving publicized discounts of 10-11 percent, it is time to reduce trade-margins on medicines. Metric-system of packaging in medicines in true spirit should be introduced by making it compulsory to pack medicines in units of 1, 2, 5, 10, 20, 50, 100, 200 or 500 gms/mltrs/kgs/litres/units unless exemption is sought for some dose-wise administration. Many drug-manufacturers pack commonly used cough-lozenges in strips of eight instead of normal ten because consumers judge price per strip rather than a lozenge. Only recently medicines like Amaryl-1, ‘Telma-40’ and ‘Glyzid-M’ have been started being marketing in strips of fifteen/thirty tablets instead of earlier ten. Idea behind such a move is to ‘over-sale’ medicines because chemists usually sell medicines in full strips only, and unused tablets/capsules in part-strip are total waste for consumers. Planning Commission’s recommendation to shift National Pharmaceutical Pricing Authority from Union Ministry of Chemicals to Union Health Ministry should be accepted.
Many-a-times name of medicine is printed only once on a complete strip of tablets/ capsules, thereby causing great confusion when the tablets/ capsules under the printed name are consumed. It is difficult to recognise medicine in balance of the strip having no name of the medicine. Authorities should make it compulsory to print name of the medicine on complete strip over every tablet/ capsule. Moreover it should also be compulsory to print/ emboss name of the medicine individually on each tablet/ capsule.
1775 Kucha Lattushah
Dariba Delhi 110006 (India)